ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMUN Immune Therapeutics Inc (PK)

0.093
0.00 (0.00%)
14 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Immune Therapeutics Inc (PK) USOTC:IMUN OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.093 0.072 0.10 0.00 01:00:00

Annual Statement of Changes in Beneficial Ownership (5)

02/04/2018 10:59pm

Edgar (US Regulatory)


FORM 5
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ] Form 3 Holdings Reported
[ ] Form 4 Transactions Reported
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

                                                                                  

OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response...
1.0
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Gostanian Richard

2. Issuer Name and Ticker or Trading Symbol

Immune Therapeutics, Inc. [imun]

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
_____ Officer (give title below)      __ X __ Other (specify below)
large share & note holder

(Last)          (First)          (Middle)

12 OLDE WOODE RD.

3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY)
12/31/2017 
(Street)

SALEM, NH 03079

(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person


Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Amount (A) or (D) Price
common   4/18/2017     P   5000   A $0.06   12949027   I   richard gostanian roth ira at etrade  
common   4/18/2017     P   10000   A $0.06   12949027   I   richard gostanian roth ira at fidelity investments  
common   4/18/2017     P   5000   A $0.058   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   4/19/2017     P   10000   A $0.0547   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   4/21/2017     P   5000   A $0.06   12949027   I   richard gostanian roth ira at fidelity investments  
common   4/21/2017     P   9000   A $0.07   12949027   I   richard gostanian roth ira at fidelity investments  
common   4/24/2017     P   20000   A $0.068   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   4/24/2017     P   25000   A $0.07   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   4/24/2017     P   20000   A $0.065   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   4/24/2017     P   10000   A $0.069   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   4/25/2017     P   10000   A $0.07   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   4/27/2017     P   5000   A $0.07   12949027   I   richard gostanian roth ira at fidelity investments  
common   4/27/2017     P   10000   A $0.08   12949027   I   richard gostanian roth ira at fidelity investments  
common   4/28/2017     P   15000   A $0.068   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   5/3/2017     P   10000   A $0.066   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   5/5/2017     P   5000   A $0.0624   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   5/16/2017     P   25000   A $0.08   12949027   I   richard gostanian roth ira at fidelity investments  
common   5/22/2017     P   5000   A $0.07   12949027   I   richard gostanian roth ira at fidelity investments  
common   5/22/2017     P   20000   A $0.05   12949027   I   richard gostanian roth ira at fidelity investments  
common   5/22/2017     P   30000   A $0.08   12949027   I   richard gostanian roth ira at fidelity investments  
common   5/22/2017     P   25000   A $0.065   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   5/23/2017     P   20000   A $0.059   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   5/23/2017     P   15000   A $0.0598   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   5/25/2017     P   20000   A $0.0518   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   6/1/2017     P   12000   A $0.0599   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   6/1/2017     P   20000   A $0.059   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   6/7/2017     P   10000   A $0.0584   12949027   I   richard gostanian & kathryn veselic joint account at etrade  
common   6/8/2017     P   25000   A $0.05   12949027   I   richard gostanian roth ira at fidelity investments  
common   6/12/2017     P   5000   A $0.06   12949027   I   richard gostanian roth ira at fidelity investments  
common   6/12/2017     P   5000   A $0.05   12949027   I   richard gostanian roth ira at fidelity investments  

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YYYY)
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
(A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Gostanian Richard
12 OLDE WOODE RD.
SALEM, NH 03079



large share & note holder

Signatures
richard gostanian 4/2/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1 Year Immune Therapeutics (PK) Chart

1 Year Immune Therapeutics (PK) Chart

1 Month Immune Therapeutics (PK) Chart

1 Month Immune Therapeutics (PK) Chart

Your Recent History